Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2018 Feb 15;45(8):1372–1381. doi: 10.1007/s00259-018-3941-3

Figure 1.

Figure 1

In vitro analysis of CD38 expression and binding ability of daratumumab to lymphoma cells. (a) Western blot analysis showed CD38 expression was highest for Ramos cells and lowest expression for HBL-1 cells among five B-cell lymphoma cell lines. (b) Flow cytometry verified the differential expression of CD38 in Ramos and HBL-1 cell lines and displayed similar binding ability of Df-conjugated daratumumab. (c) Cellular binding assay showed 89Zr-Df-daratumumab bound specifically to Ramos cells, with a Ka value of 1.29 ± 0.39 nM.